10-Q · May 15, 2026
Galectin Therapeutics (GALT) reported negative earnings with no revenue and an EPS of -0.08 for Q4 2026, reflecting a narrowing loss compared to -0.12 the previous quarter. Management highlighted a significant decrease…
Earnings analysis · 10-Q
GALT earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
The filing does not provide reported revenue, margins, current-quarter EPS, cash flow, or segment results, so operating trends versus the prior quarter or prior year cannot be assessed. The key balance-sheet development…
Read full summary
The filing does not provide reported revenue, margins, current-quarter EPS, cash flow, or segment results, so operating trends versus the prior quarter or prior year cannot be assessed. The key balance-sheet development was the July 31, 2026 conversion of approximately $105.8 million of principal and accrued interest into 34,376,167 shares, while a $10.0 million facility remained undrawn and available. The transaction materially reduced debt but increased dilution and shareholder-control risks, and the company continues to report 1 material weakness in internal controls as of June 30, 2026.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Eliminated $105.8M of debt and interest
The July 31, 2026 debt conversion eliminated $91.0 million of principal and approximately $14.8 million of accrued interest, or approximately $105.8 million in total liabilities.
-
$10.0M credit facility remains available
The December 2025 supplemental line remains outstanding, undrawn, and available, providing access to a $10.0 million credit facility.
-
Debt converted without cash repayment
The conversion issued 34,376,167 common shares at a blended average conversion price of approximately $3.07 per share, reducing near-term debt obligations without a cash repayment.
-
Post-conversion capital structure disclosed
Following the transaction, approximately 100,849,644 common shares and 197,500 Series A Voting Preferred shares were outstanding.
What to watch
-
Material shareholder dilution
The issuance of 34,376,167 shares increased the share count to approximately 100,849,644 common shares, creating material dilution for existing holders.
-
Concentrated shareholder control
Richard E. Uihlein beneficially owns approximately 44.3% of actual voting power and approximately 49.3% including shares issuable upon warrant exercise, creating significant concentration of control.
-
Material internal-control weakness persists
Management concluded disclosure controls were not effective as of June 30, 2026 because of 1 material weakness involving valuation controls for derivative liabilities tied to contingent interest on convertible notes; the weakness creates a reasonable possibility of a material misstatement not being detected timely.
-
Potential resale registration overhang
The 34,376,167 shares issued in the conversion are unregistered and subject to resale restrictions, but the company must file a resale registration statement within 180 days after receiving a registration request notice.
-
Limited remaining funding capacity
The filing refers investors to the risk factors in the 2025 Form 10-K and does not identify additional risk-factor changes; the company nevertheless continues to face funding risk despite only $10.0 million remaining available under the undrawn facility.
Management's outlook
No quantitative revenue, EPS, operating, or cash-flow guidance was provided in the filing.
Earlier filings 4
10-K · March 31, 2026
Galectin Therapeutics (GALT) is a clinical-stage biopharma focused on its galectin-3 inhibitor belapectin for prevention of esophageal varices in MASH cirrhosis; the company reported mixed NAVIGATE trial results…
10-Q · November 14, 2025
Galectin Therapeutics reported a Q3 net loss of $8,184,000 (EPS $(0.13)), an improvement versus Q3 2024 net loss of $11,220,000 (EPS $(0.18)), driven by sharply lower operating expenses. However, liquidity and…
10-Q · May 15, 2025
Galectin reported Q1 2025 net loss per share of $(0.15), an improvement from $(0.19) in Q1 2024, driven by lower operating expenses (total operating expenses $7,897k vs $9,648k). However, cash declined to $7,431k at…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.